Everything below concerns melanotan-2. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
The Bain de Soleil brand transitioned from Procter & Gamble (P&G) to Pfizer in August 1995. The product recipes and certain pieces of manufacturing and packaging equipment were relocated from Hatboro, PA (P&G) to Pfizer Consumer Healthcare Group in Parsippany, New Jersey around October 1995. From November 1995 to 1999, the product was manufactured and packaged at the Pfizer CHCG 100 Jefferson Road, Parsippany, NJ site. During this time, the brand saw the largest portfolio enlargement, including self-tanning (sunless) and after-sun products. These products were all formulated at the same Pfizer site at the 400 Webro Road laboratories. Between 1995 and 1999, the following Bain de Soleil products were marketed:
The deal also stated that Israel would retain "complete military freedom of action" to attack Lebanon in the event of a violation of the agreement by Hezbollah or another entity in Lebanon. Prime Minister of Lebanon Najib Mikati issued strong support for the agreement and urged the international community to help implement the agreement immediately in order to "halt Israeli aggression". On 27 November, thousands of displaced Lebanese began to return to areas ruined by Israeli strikes.
==== Coal ==== Coal contains a small amount of radioactive uranium, barium, thorium, and potassium, but, in the case of pure coal, this is significantly less than the average concentration of those elements in the Earth's crust. The surrounding strata, if shale or mudstone, often contain slightly more than average and this may also be reflected in the ash content of 'dirty' coals. The more active ash minerals become concentrated in the fly ash precisely because they do not burn well. The radioactivity of fly ash is about the same as black shale and is less than phosphate rocks, but is more of a concern because a small amount of the fly ash ends up in the atmosphere where it can be inhaled. According to U.S. National Council on Radiation Protection and Measurements (NCRP) reports, population exposure from 1000-MWe power plants amounts to 490 person-rem/year for coal power plants, 100 times as great as nuclear power plants (4.8 person-rem/year). The exposure from the complete nuclear fuel cycle from mining to waste disposal is 136 person-rem/year; the corresponding value for coal use from mining to waste disposal is "probably unknown".
== Mechanism of action == Orforglipron is a small-molecule, partial GLP-1 receptor agonist affecting the activity of cyclic adenosine monophosphate (cAMP); its effects are similar to the actions of glucagon-like peptide-1 (GLP-1) for reducing food intake and lowering blood glucose levels.
Sources: en.wikipedia.org
=== Add-on therapy === Hyperbaric oxygen (HBO): In theory, HBO decreases local inflammation in the wound and bolsters the body's immune response. However, the impact of HBO on patients with NSTIs remains unclear. Intravenous immunoglobulin (IVIG): IVIG is intended to combat the exotoxins released by S. pyogenes toxic shock syndrome (TSS). However, studies have failed to find any effect on patient mortality. There may also be serious adverse effects with IVIG use. AB103: Reltecimod, aka AB103, is a new drug that binds to the CD28 T-cell receptor and thus mitigates the effects of bacterial toxins. Studies show that it may decrease the severity of organ failure in NF patients. However, other studies found no difference in mortality with this therapy. Supportive therapy: Intravenous hydration, wound care, anticoagulants to prevent thromboembolic events, pain control, vasopressors, etc., should always be provided to patients when appropriate.
== See also == Good Automated Manufacturing Practice (GAMP) Verification and Validation Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme Regulation of therapeutic goods United States Pharmacopeia
Freeman made six appearances in various films in 2005. In the drama An Unfinished Life, Freeman plays Mitch, a neighbor of a Wyoming rancher (Robert Redford). The film had a mixed response; The Guardian critic thought it was amiable but questioned the purpose of Freeman's "sidekick" role. Freeman's authoritative voice led to his narration of two documentaries; Steven Spielberg's War of the Worlds and the Academy Award-winning March of the Penguins. He also appeared in Christopher Nolan's Batman Begins, the first installment in what would become The Dark Knight Trilogy, as the fictional Lucius Fox. After this, he co-starred with Jet Li in the action-thriller Unleashed, playing Sam, a blind piano tuner who helps Li's character turn his life around. The film gained a mixed-to-positive reception; Peter Hartlaub of San Francisco Chronicle was confused with the genre and thought Freeman's character interrupted the narrative. Freeman's next role was in the thriller Edison, which bombed at the box office. In his last release of 2005, he provided the voice of Neil Armstrong in the documentary Magnificent Desolation: Walking on the Moon 3D. Freeman starred in 2006's The Contract, as assassin Frank Carden opposite John Cusack. The film was released direct-to-video, which critic John Cornelius suggests was unsurprising, considering the generic formula of the thriller. Freeman next appeared in Lucky Number Slevin (2006), a crime thriller directed by Paul McGuigan.
"Energy-efficient production of plasma-activated water: insights into controllable peroxynitrite chemistry". Green Chemistry. 27 (14): 3715–3726. doi:10.1039/d5gc00080g. Vyas, Heema Kumari Nilesh (20 November 2025). "Plasma-activated water: a powerful tool against pesky biofilms". Microbiology Australia. 46 (4): 213–217. doi:10.1071/MA25060.
== Resilience of agrifood systems == The resilience of agrifood systems refers to the capacity over time of agrifood systems, in the face of any disruption, to sustainably ensure availability of and access to sufficient, safe and nutritious food for all, and sustain the livelihoods of agrifood systems' actors. According to FAO, truly resilient agrifood systems must have a robust capacity to prevent, anticipate, absorb, adapt and transform in the face of any disruption, with the functional goal of ensuring food security and nutrition for all and decent livelihoods and incomes for agrifood systems' actors. Such resilience addresses all dimensions of food security, but focuses specifically on stability of access and sustainability, which ensure food security in both the short and the long term.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.